ACTRN12623001333606尚未招募2 期
The Novel use of Labetuzumab as Adjuvant Immunotherapy in Patients with Primary Colon Adenocarcinoma with Intact PELPK Binding Motif in their CEACAM5 gene in a Phase II clinical trial regarding the Development of Metachronous Liver Metastases (i.e., those at ‘high-risk’ of metachronous CRCLMs)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Patients with suspected or confirmed colon adenocarcinoma (on histopathology) who are undergoing surgical resection at St George Hospital, Sydney
排除标准
- •Those who would be beyond 6 weeks post-operatively or had previous bowel cancer/resections.
研究者
相似试验
进行中（未招募）
1 期
Will a single dose of Rituximab treatment, when taken with anti thyroid drugs for 1 year, stop the over-activity of the thyroid gland from returning once you stop ATD treatment?EUCTR2016-000209-35-GBewcastle upon Tyne Hospitals NHS Foundation Trust27
招募中
不适用
Alemtuzumab or rituximab induction in ABO-incompatible kidney transplantation.ABO-incompatible kidney transplantation.Dutch:bloedgroep ABO-incompatible niertransplantatie.NL-OMON28980investigator-drivenErasmus Medical Center Rotterdam100
进行中（未招募）
2 期
Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate CancerProstate CancerNCT02923180Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins33
进行中（未招募）
1 期
Immunotherapy in neoadjuvant and adjuvant setting in patients with advanced HCC treated by electroporation in curative intent: French multicenter phase 2 therapeutic trial - NIVOLEPivolumab in neoadjuvant and adjuvant setting in patients with advanced HCC treated by electroporationMedDRA version: 20.0Level: PTClassification code 10073071Term: Hepatocellular carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004679-29-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)50
招募中
2 期
eo-adjuvant Pembrolizumab as an alternative treatment for MMRd uterine cancer, a phase II efficacy studyNL-OMON53535niversitair Medisch Centrum Groningen12